PRE — Prenetics Global Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1876431 ·
Last close
$21.82
Market Cap
$331.63M
52W High
$22.75
52W Low
$15.91
ADV30
231,688
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 35,954,000 | 23,283,000 | -9,706,000 | -23,104,000 | 175,302,000 | 56,017,000 | 54,280,000 |
| Dec 2025 | 36,558,000 | 21,588,000 | -13,136,000 | -7,501,000 | 206,073,000 | 32,131,000 | 49,707,000 |
| Sep 2025 | 23,555,000 | 14,024,000 | -6,559,000 | -7,408,000 | 196,507,000 | 13,264,000 | 35,305,000 |
| Jun 2025 | 17,680,000 | 7,289,000 | -9,869,000 | -12,410,000 | 199,106,000 | 17,249,000 | 48,214,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,382,000
Investing CF
$30,191,000
Financing CF
$-14,619,000
CapEx
—
Dividends Paid
$0
Buybacks
$-13,117,000
EPS Diluted TTM
$-3.63
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-554,781,000
Inventory
$14,198,000
Receivables
$11,875,000
ST Investments
$50,018,000
EBIT TTM
$-36,932,000
Pretax Income TTM
$-54,699,000
Interest Exp TTM
$234,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$154,592,992
EBITDA
$-54,805,000
Free Cash Flow
$-36,112,376
Enterprise Value
$220,811,872
Total Cash
$128,557,000
Total Debt
$682,000
Shares Out
15,198,385
Trailing EPS
$-3.46
Book Value
$5.39
ROE
-47.0%
ROA
-18.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 92,390,000 | -38,129,000 | -37,709,000 | 206,073,000 | 49,707,000 | — | -21,826,000 |
| Dec 2024 | 15,936,000 | -38,277,000 | -46,304,000 | 213,575,000 | 42,229,000 | — | -28,874,000 |
| Dec 2023 | 6,155,000 | -42,469,000 | -62,724,000 | 254,171,000 | 44,013,000 | — | -13,765,000 |
| Dec 2022 | 13,164,000 | -65,917,000 | -190,454,000 | 312,131,231 | 68,668,371 | — | 14,515,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.94
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $21.82 · call volume: 77 · put volume: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMRX | Immuneering Corp | $335.13M | $5.18 | — |
| IRD | Opus Genetics, Inc. | $335.28M | $4.03 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $322.27M | $5.33 | — |
| PRQR | ProQR Therapeutics N.V. | $342.92M | $2.43 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $346.54M | $6.06 | — |
News headlines (Yahoo Finance, 1h cache)
Prenetics Global Ltd (PRE) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...
2026-08-21 01:02 · Yahoo
Prenetics Global Q2 Earnings Call Highlights
2026-08-18 15:02 · Yahoo
Prenetics’ IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expect
2026-08-18 14:07 · Yahoo
PRE Continues to Exceed Expectations and Receive Preferential Financing
2026-07-15 12:05 · Yahoo
Sector Update: Healthcare Stocks Fall Late Afternoon
2026-07-14 19:46 · Yahoo
Prenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market Growth
2026-06-25 12:43 · Yahoo
CEO Chat with Danny Yeung, Co-Founder and CEO of Prenetics Global
2026-06-23 16:54 · Yahoo
Prenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion
2026-06-04 12:30 · Yahoo
Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder
2026-05-20 20:51 · Yahoo
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
2026-05-20 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.